UK Approves Orforglipron for Weight Management and Type 2 Diabetes
On August 10, 2026, the Medicines and Healthcare products Regulatory Agency (MHRA) granted authorization for orforglipron (Foundayo), marking a significant milestone as the UK becomes the first European nation to approve this GLP-1 receptor agonist for weight management and type 2 diabetes. This medication is prescribed alongside a reduced-calorie diet and increased physical activity, specifically for adults who have a body mass index (BMI) of 30 or higher, or a BMI between 27 and 30 with at least one weight-related comorbidity. Additionally, orforglipron is indicated to enhance glycaemic control in patients whose type 2 diabetes is not adequately managed.
The MHRA expressed satisfaction with the rigorous assessment process that orforglipron underwent, ensuring its safety, quality, and effectiveness. As a prescription-only medication, orforglipron will be closely monitored by the MHRA to ensure ongoing safety and efficacy.
Orforglipron is administered as a daily tablet, which can be taken at any time without food or water restrictions. The treatment regimen begins with a dose of 0.8 mg, which can be gradually increased through several levels—2.5 mg, 5.5 mg, 9 mg, 14.5 mg, and up to 17.2 mg—allowing for a minimum of one month at each dose to assess tolerance and effectiveness. Patients are advised to adhere to the instructions provided in the Patient Information Leaflet.
This medication mimics the action of the naturally occurring hormone glucagon-like peptide-1 (GLP-1), which is released after eating and plays a crucial role in appetite regulation. By acting on specific brain areas, orforglipron helps individuals feel fuller for longer, thereby reducing hunger and food cravings, which can assist in weight reduction when combined with appropriate dietary and lifestyle changes. For individuals with type 2 diabetes, orforglipron also aids in lowering blood sugar levels when they are elevated.
Common side effects associated with orforglipron include nausea, constipation, diarrhea, vomiting, dyspepsia (indigestion), and abdominal pain. While the medication has received approval for use in the UK, it is not yet available through the National Health Service (NHS). Decisions regarding its inclusion in NHS offerings will follow established protocols, including evaluation by the National Institute for Health and Care Excellence (NICE).
As a prescription-only medication, orforglipron must be obtained through a registered pharmacy with a doctor's prescription. It is illegal to promote prescription medications directly to the public, and purchasing such medications from unregulated sources poses significant health risks.
Patients experiencing side effects are encouraged to consult their healthcare provider and report any adverse reactions through the Yellow Card scheme, which can be accessed via the MHRA's website or through mobile applications available on major platforms.
The authorization of orforglipron for weight management and type 2 diabetes was granted to Eli Lilly on August 10, 2026. Further details will be available in the Summary of Product Characteristics and Patient Information leaflets, which are expected to be published on the MHRA Products website within a week of the approval. The MHRA, as an executive agency of the Department of Health and Social Care, is tasked with regulating all medicines and medical devices in the UK, ensuring their safety and effectiveness through robust, evidence-based evaluations.




